Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643164 | 0.83 | KMT2A (0.53) | LMNAMAPTELANEHSD17B10ESR1 | |
| SCHEMBL6667696 | 0.81 | LMNA (0.57) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL10599534 | 0.80 | HTR2A (0.42) | LMNAPOLBELANEALDH1A1KMT2A | |
| SCHEMBL12185174 | 0.79 | LMNA (0.55) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL8033783 | 0.79 | ALDH1A1 (0.62) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL7773803 | 0.78 | LMNA (0.53) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL10286400 | 0.78 | LMNA (0.53) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL6666839 | 0.78 | LMNA (0.53) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL17613165 | 0.78 | IDO1 (0.57) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL26084830 | 0.78 | LMNA (0.53) | LMNAMAPTPOLBPKMELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1081 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| EP-1207890-A2 | ANTIVIRAL PRODRUGS | ICN Pharmaceuticals, Inc. (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2001068034-B1 | 1, 2, 4-TRIAZOLORIBONUCLEOSIDE PRODRUGS AND THEIR ADMINISTRATION TO TREAT VIRAL DISEASE CONDITIONS | ICN PHARMACEUTICALS (US) | 2002-05-10 | — | — | WO | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2001068034-A2 | 1, 2, 4-TRIAZOLORIBONUCLEOSIDE PRODRUGS AND THEIR ADMINISTRATION TO TREAT VIRAL DISEASE CONDITIONS | RIBAPHARM CORP. (US) | 2001-09-20 | — | — | WO | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | LMNA 2067/4885MAPT 11/4885POLB 2154/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | LMNA 2144/4885MAPT 10/4885POLB 1829/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | LMNA 2308/4885MAPT 6/4885POLB 2558/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | LMNA 1436/4885MAPT 10/4885POLB 1473/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | LMNA 2454/4885MAPT 5/4885POLB 2600/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | LMNA 2067/4885MAPT 11/4885POLB 2154/4885 |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | PSEN2, PSEN1, CHAT | LMNA 1737/4885MAPT 6/4885POLB 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.